Magnacor Therapeutics develops small‑molecule inhibitors that eradicate intracellular bacterial pathogens, such as Porphyromonas gingivalis, implicated in atherosclerotic plaque formation and inflammation.
Funding
Funding not disclosed
Founders
Product
Problem
Cardiovascular disease remains a leading cause of death, driven by chronic inflammation and atherosclerotic plaque rupture. Conventional therapies do not address intracellular bacterial pathogens that have been identified within plaques, leaving a gap in preventing heart attacks and strokes for patients with multiple risk factors.
Solution
Magnacor Therapeutics develops small‑molecule inhibitors that target intracellular pathogens, particularly Porphyromonas gingivalis, implicated in plaque formation and inflammation. Their discovery platform combines high‑throughput screening of drug libraries with in‑vitro infection models to identify compounds that eradicate these bacteria inside vascular cells. Lead candidates have demonstrated significant plaque reduction in animal models, and one compound already holds FDA approval, facilitating accelerated development. The company is advancing these agents toward human trials to provide a novel anti‑infective approach for atherosclerosis and related chronic inflammatory conditions.
Target Audience
Primary customers are pharmaceutical partners and biotech companies seeking novel cardiovascular therapeutics, as well as clinical researchers focused on inflammation‑driven heart disease.
Features
- High‑throughput screening pipeline focused on inhibitors of intracellular bacterial pathogens linked to atherosclerosis
- In‑vitro cellular assays that evaluate compound efficacy against P. gingivalis within vascular cells and biofilms
- Preclinical animal studies showing robust reduction of atherosclerotic plaque burden
- Patent‑protected novel antimicrobial chemistry specific to intracellular targets
- Leveraging an FDA‑approved molecule to streamline regulatory pathways for the lead therapeutic